Detailed information for compound 371352

Basic information

Technical information
  • TDR Targets ID: 371352
  • Name: 2-[4-(2,5-dimethylpyrrol-1-yl)phenyl]sulfanyl acetic acid
  • MW: 261.339 | Formula: C14H15NO2S
  • H donors: 1 H acceptors: 2 LogP: 3.23 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: OC(=O)CSc1ccc(cc1)n1c(C)ccc1C
  • InChi: 1S/C14H15NO2S/c1-10-3-4-11(2)15(10)12-5-7-13(8-6-12)18-9-14(16)17/h3-8H,9H2,1-2H3,(H,16,17)
  • InChiKey: DASVXRJADIYRNJ-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 2-[[4-(2,5-dimethyl-1-pyrrolyl)phenyl]thio]acetic acid
  • 2-[4-(2,5-dimethylpyrrol-1-yl)phenyl]sulfanylethanoic acid
  • 2-[[4-(2,5-dimethylpyrrol-1-yl)phenyl]thio]acetic acid
  • 131817-93-1
  • Oprea1_564740
  • ST5008603
  • CBMicro_038314
  • NSC731231
  • ChemDiv2_000618
  • Oprea1_159453
  • BAS 01305913
  • [4-(2,5-Dimethyl-pyrrol-1-yl)-phenylsulfanyl]-acetic acid
  • BIM-0038342.P001

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens elastase, neutrophil expressed Starlite/ChEMBL References
Staphylococcus aureus DnaC helicase Starlite/ChEMBL References
Homo sapiens dual specificity phosphatase 3 Starlite/ChEMBL References
Bacillus anthracis Anthrax lethal factor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma mansoni Replicative DNA helicase Get druggable targets OG5_131890 All targets in OG5_131890
Mycobacterium tuberculosis Probable replicative DNA helicase DnaB Get druggable targets OG5_131890 All targets in OG5_131890
Treponema pallidum replicative DNA helicase (dnaB) Get druggable targets OG5_131890 All targets in OG5_131890
Trichomonas vaginalis pps1 dual specificty phosphatase, putative Get druggable targets OG5_134995 All targets in OG5_134995
Entamoeba histolytica dual specificity protein phosphatase, putative Get druggable targets OG5_134995 All targets in OG5_134995
Mycobacterium ulcerans replicative DNA helicase DnaB Get druggable targets OG5_131890 All targets in OG5_131890
Wolbachia endosymbiont of Brugia malayi replicative DNA helicase Get druggable targets OG5_131890 All targets in OG5_131890
Chlamydia trachomatis replicative DNA helicase Get druggable targets OG5_131890 All targets in OG5_131890
Mycobacterium leprae PROBABLE REPLICATIVE DNA HELICASE DNAB replicative DNA helicase Get druggable targets OG5_131890 All targets in OG5_131890
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus transmembrane protease serine 3 elastase, neutrophil expressed 267 aa 236 aa 27.5 %
Trypanosoma brucei kinetoplastid-specific dual specificity phosphatase, putative dual specificity phosphatase 3 185 aa 182 aa 25.3 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Mycobacterium tuberculosis Probable replicative DNA helicase DnaB 0.0778 1 0.5
Mycobacterium leprae PROBABLE REPLICATIVE DNA HELICASE DNAB replicative DNA helicase 0.0778 1 0.5
Treponema pallidum replicative DNA helicase (dnaB) 0.0778 1 0.5
Wolbachia endosymbiont of Brugia malayi replicative DNA helicase 0.0778 1 0.5
Trichomonas vaginalis pps1 dual specificty phosphatase, putative 0.07 0 0.5
Mycobacterium ulcerans replicative DNA helicase DnaB 0.0778 1 0.5
Schistosoma mansoni Replicative DNA helicase 0.0778 1 0.5
Entamoeba histolytica dual specificity protein phosphatase, putative 0.07 0 0.5

Activities

Activity type Activity value Assay description Source Reference
Activity (binding) Inhibition of human chymotrypsin at 160 uM ChEMBL. 16913712
Activity (binding) Inhibition of human plasma kallikrein at 160 uM ChEMBL. 16913712
Activity (binding) Inhibition of human MMP9 at 160 uM ChEMBL. 16913712
Activity (binding) Inhibition of porcine aminopeptidase M at 160 uM ChEMBL. 16913712
Activity (binding) 0 Inhibition of human MMP9 at 160 uM ChEMBL. 16913712
Activity (binding) 0 Inhibition of human plasma kallikrein at 160 uM ChEMBL. 16913712
Activity (binding) 0 Inhibition of human chymotrypsin at 160 uM ChEMBL. 16913712
Activity (binding) 0 Inhibition of porcine aminopeptidase M at 160 uM ChEMBL. 16913712
CC50 (ADMET) > 100 uM Cytotoxicity against human HeLa cells by MTT assay ChEMBL. 19477652
IC50 (binding) = 2.9 uM Inhibition of Anthrax lethal factor activity by microplate assay ChEMBL. 16913712
IC50 (binding) = 2.9 uM Inhibition of Anthrax lethal factor activity by microplate assay ChEMBL. 16913712
IC50 (binding) = 4 uM Inhibition of Staphylococcus aureus Smith DNA helicase DnaC assessed as strand unwinding after 30 mins by FRET assay ChEMBL. 19477652
IC50 (binding) = 15.5 uM Inhibition of human neutrohil elastase ChEMBL. 16913712
IC50 (binding) = 15.5 uM Inhibition of human neutrohil elastase ChEMBL. 16913712
IC50 (binding) = 58.3 uM Inhibition of human cathepsin B ChEMBL. 16913712
IC50 (binding) = 58.3 uM Inhibition of human cathepsin B ChEMBL. 16913712
Ki (binding) = 1.6 uM Binding affinity to Anthrax lethal factor ChEMBL. 16913712
Ki (binding) = 1.6 uM Binding affinity to Anthrax lethal factor ChEMBL. 16913712
Ki (binding) = 2.09 uM Inhibition of recombinant vaccina H1-related phosphatase expressed in Escherichia coli by Michaelis-Menten kinetic studies ChEMBL. 19888758
Ki (binding) 2.09 uM PUBCHEM_BIOASSAY: SAR Colorimetric assay for the identification of compounds that inhibit VHR1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1654, AID1661, AID1878, AID1957, AID1958, AID1992, AID2074, AID2082, AID2083] ChEMBL. No reference
Ki (binding) = 4.6 uM Binding affinity to Anthrax lethal factor-substrate complex ChEMBL. 16913712
Ki (binding) = 4.6 uM Binding affinity to Anthrax lethal factor-substrate complex ChEMBL. 16913712

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.